A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) is a phase 3 interventional study registered as NCT06136650, led by Merck Sharp & Dohme, and recruiting on the registry. Official title: MK-5684-004: A Phase 3, Randomised, Open-label Study of Opevesostat Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment With One Next-generation Hormonal Agent (NHA) (OMAHA-004). Planned enrolment is 1314 participants (estimated). The study started in 2023-12-18 and primary completion is expected in 2028-05-10. No results have been posted on ClinicalTrials.gov.